Young Investigator Prize Research Articles

The potentially protective effect of lithium on the risk of osteoporosis: A nationwide study of 22,912 patients with bipolar disorder

IntroductionOsteoporosis, a systemic skeletal disorder associated with substantial morbidity and mortality, has been suggested to be particularly common among individuals with bipolar disorder. Lithium, a mood-stabilizer used as first-line treatment for bipolar disorder, may have bone-protecting properties.ObjectivesWe aimed to subject both of these hypotheses to further examination in a nationwide register-based study.MethodsWe compared the incidence of osteoporosis, identified via hospital discharge diagnoses and prescribed medications, between all individuals diagnosed with bipolar disorder and age- and sex-matched controls from the general population (earliest start of follow-up at the age of 40 years) using Cox regression. Subsequently, we followed the patients with bipolar disorder and identified all prescriptions for mood-stabilizing medications. Using Cox regression, we compared the incidence of osteoporosis for patients using lithium, antipsychotics or anticonvulsants, respectively, with that of patients not using these medications.ResultsWe followed 22,912 patients with bipolar disorder (median age 50.4 years, 43.4% men) and 114,560 matched controls for 1,215,698 person-years. The incidence of osteoporosis per 1,000 person-years was 8.70 (95%CI:8.28-9.14) among patients with bipolar disorder and 7.84 (95%CI:7.67-8.01) among controls, resulting in a hazard rate ratio (HRR) of 1.15 (95%CI:1.09-1.21). Lithium treatment was associated with reduced risk of osteoporosis (HRR=0.62; 95%CI:0.53-0.72) in a treatment-duration-response-like manner. Treatment with antipsychotics and anticonvulsants was not associated with reduced risk of osteoporosis.ConclusionsThis is the first longitudinal study to show that the risk of osteoporosis is elevated among patients with bipolar disorder, and that treatment with lithium is associated with reduced risk of osteoporosis.DisclosureDr. Østergaard has received the 2020 Lundbeck Foundation Young Investigator Prize. Furthermore, SDØ owns units of mutual funds with stock tickers DKIGI, DKIDKIX, MAJGRO, NBIDE, SPIC20CAPK, SPVILRKL and WEKAFKI.

Clinical validation of the self-rated 6-item Hamilton Depression Rating Scale among inpatients

IntroductionMeasurement-based care (i.e., the systematic use of rating scales to guide clinical decision-making) has shown great promise in the treatment of major depression in clinical trials. Unfortunately, measurement-based care has not yet gained ground in clinical practice, possibly because clinician-rated scales are time-consuming and limited by the availability of trained raters. Hence, brief and valid self-rated scales (questionnaires) may serve as an alternative or supplement to clinician-rated scales. The self-rated 6-item Hamilton Depression Rating Scale (HAM-D6-SR) has shown some promise in this regard, but its validity among inpatients remains unclear.ObjectivesThe objective of this study is to evaluate the criterion validity and responsiveness (sensitivity to change) of the HAM-D6-SR among inpatients using the clinician-rated 17-item Hamilton Rating Scale for Depression (HAM-D17) as gold standard reference.MethodsInpatients with depression will complete the HAM-D6-SR twice during admission (at least one week between the two self-ratings). At both occasions, the patients will subsequently be rated on the HAM-D17 by trained raters, who are blind to the HAM-D6-SR ratings. The agreement between the HAM-D6-SR and the HAM-D6 extracted from the HAM-D17 will be evaluated using intra-class correlation.ResultsA total of 100 inpatients will be recruited for the study. Data collection is ongoing, and the results of the study will be presented at the 2022 EPA meeting.ConclusionsIf the agreement between the HAM-D6-SR and the HAM-D6 extracted from the HAM-D17 is satisfactory, the HAM-D6-SR could inform decision-making in the treatment of depression.DisclosureThe presenting author, PK, declares no conflict of interests. Co-author, SDØ, has received the 2020 Lundbeck Foundation Young Investigator Prize. Furthermore, SDØ owns units of mutual funds with stock tickers DKIGI, DKIDKIX, MAJGRO, NBIDE, SPVILRKL and WE

0114 Morning Stimulant Administration Reduces Sleep and Overnight Working Memory Improvement

Abstract Introduction The goal of cognitive enhancement is to improve mental functions using interventions including cognitive training, brain stimulation and pharmacology. Indeed, psychostimulants, commonly used for cognitive enhancement purposes, while preventing sleep, have been shown to increase working memory (WM) and attention. WM is widely believed play a core role in cognitive ability, and has been shown to correlate with broad measure of cognitive ability and fluid intelligence. Sleep, however, is also important for cognitive function; thus, understanding the interaction between stimulants, sleep and cognition may inform current approaches to cognitive enhancement. Methods We used a double-blind, placebo controlled, repeated-measure design to investigate the effect of morning administration (9am) of stimulant, dextroamphetamine (DEX, 20 mg), on within-day and overnight WM performance, and sleep in 46 (22 female) healthy young adults. We tested WM using an operation span task (OSPAN) as it engages and captures both the memory retention and online processing capacity of WM. WM was tested at 75 minutes post drug, 12 h post drug, and 24 h post drug over a night of sleep. Results Compared with placebo, DEX showed no changes to WM performance at 75min or 12-hr post-drug. After sleep, DEX performed worse than PBO and the overnight improvement in performance in the PBO condition was absent in the DEX condition. Moreover, sleep quality was negatively affected by DEX administration. Conclusion In summary, we found no cognitive boost from psychostimulants across a day of wake and a blockade of overnight WM increases with the stimulant, compared to PBO. Given the growing non-medical use of stimulants in young adults, these findings have important implications for assessing their benefit for cognitive enhancement. Support Office of Naval Research N00014-14-1-0513 (S.M.) and DoD Young Investigator Prize (S.M.)

Endings and New Beginnings

Endings and New Beginnings

Kallol Ray

Angewandte Chemie International EditionVolume 57, Issue 28 p. 8366-8366 Author ProfileFree Access Kallol Ray First published: 16 February 2018 https://doi.org/10.1002/anie.201801205AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Graphical Abstract When I was eighteen I wanted to be a fighter pilot in the Indian air force. The natural talent I would like to be gifted with is the ability to see the future ...” This and more about Kallol Ray can be found on page 8366. Kallol Ray The author presented on this page has recently published his 10th article in Angewandte Chemie in the last 10 years: “A Highly Reactive Oxoiron(IV) Complex Supported by a Bioinspired N3O Macrocyclic Ligand”: I. Monte Pérez, X Engelmann, Y.-M. Lee, M. Yoo, E. Kumaran, E. R. Farquhar, E. Bill, J. England, W. Nam, M. Swart, K. Ray, Angew. Chem. Int. Ed. 2017, 56, 14384; Angew. Chem. 2017, 129, 14576. The work of K. Ray has been featured on the inside cover of Angewandte Chemie: “Oxidation Reactions with Bioinspired Mononuclear Non-Heme Metal–Oxo Complexes”: X. Engelmann, I. Monte-Pérez, K. Ray, Angew. Chem. Int. Ed. 2016, 55, 7632; Angew. Chem. 2016, 128, 7760. Date of birth: December 13, 1978 Position: Professor of Inorganic Chemistry, Humboldt-Universität zu Berlin E-mail: kallol.ray@chemie.hu-berlin.de Homepage: https://www.chemie.hu-berlin.de/en/forschung-en/ray/ray-en/kallolray ORCID: 0000-0003-2074-8844 Education: 2001 MSc, Indian Institute of Technology, Kanpur 2005 PhD supervised by Prof. Dr. Karl Wieghardt, Ruhr-Universität Bochum and Max Planck Institute (MPI) for Bioinorganic Chemistry, Mülheim an der Ruhr 2005–2006 Postdoctoral position with Prof. Dr. Karl Wieghardt, MPI for Bioinorganic Chemistry 2006–2009 Postdoctoral position with Prof. Dr. Lawrence Que, Jr., University of Minnesota Awards: 2012 Ernst Haage Prize, MPI for Chemical Energy Conversion; 2013 Wöhler–EurJIC Young Investigator Prize; 2015 Carl Duisberg Memorial Award, GDCh; 2016 Heisenberg Professorship, DFG. Current research interests: Bioinspired catalysis; organometallic chemistry; water oxidation reactions; activation of C−H bonds; fuel cells; recyclable energy sources Hobbies: Cricket, soccer, fitness, wine tasting When I was eighteen I wanted to be a fighter pilot in the Indian air force. The natural talent I would like to be gifted with is the ability to see the future. The secret of being a successful scientist is to learn how to deal with criticism in life. My favorite molecule is hopefully yet to be discovered from an unexpected reaction in my laboratory. If I had one year of paid leave I would use the time to teach my kids my mother tongue Bengali. The principal aspect of my personality is impatience. What I appreciate most about my friends is that they accept me with all my flaws. Chemistry is fun because it is sometimes too difficult even for chemists to understand. My favorite drink is a Zombie. In a spare hour, I … wish I had that luxury. My favorite quote is “Don't criticize what you can't understand” (Bob Dylan). My biggest inspiration is my parents. I advise my students to be even (over)confident rather than being insecure in their lives. My 5 top papers: 1“Temperature Dependence of the Catalytic Two- versus Four-Electron Reduction of Dioxygen by a Hexanuclear Cobalt Complex”: I. Monte-Pérez et al., J. Am. Chem. Soc. 2017, 139, 15033. (A deep understanding of the factors that control 2e−/2H+ vs. 4e−/4H+ reductions of dioxygen.) 2“Redox Non–innocence of a N–Heterocyclic Nitrenium Cation Bound to a Nickel–Cyclam Core”: F. Heims, F. F. Pfaff, S.-L. Abram, E. R. Farquhar, M. Bruschi, C. Greco, K. Ray, J. Am. Chem. Soc. 2014, 136, 582. (The coordination chemistry of an N-heterocyclic nitrenium ion to a first-row transition metal and its implication in catalysis.) 3“A High-Valent Heterobimetallic [CuIII(μ-O)2NiIII]2+ Core involving Nucleophilic Oxo Groups”: S. Kundu et al., Angew. Chem. Int. Ed. 2013, 52, 5622; Angew. Chem. 2013, 125, 5732 (Novel reactivity patterns of heterodinuclear bis(μ-oxo) complexes compared to their homodinuclear analogues.) 4“Lewis Acid Trapping of an Elusive Copper–Tosylnitrene Intermediate Using Scandium Triflate”: S. Kundu, E. Miceli, E. Farquhar, F. F. Pfaff, U. Kuhlmann, P. Hildebrandt, B. Braun, C. Greco, K. Ray, J. Am. Chem. Soc. 2012, 134, 14710. (The long-sought reactive intermediate that is believed to be involved in the copper-mediated amination and aziridination reactions was trapped.) 5“An Oxocobalt(IV) Complex Stabilized by Lewis Acid Interactions with Scandium(III) Ions”: F. F. Pfaff et al., Angew. Chem. Int. Ed. 2011, 50, 1711; Angew. Chem. 2011, 123, 1749. (We trapped the elusive intermediate that is postulated to occur in cobalt-mediated oxidation reactions.) Volume57, Issue28July 9, 2018Pages 8366-8366 ReferencesRelatedInformation

EUROSON 2017 EFSUMB Young Investigator Prize Winners

Joint First Prize – Technical Presentation Ruud JG van Sloun – The Netherlands Maria Theodorou – UK

Call for Candidates for the EuPA Young Investigator Prize (PhD)

Call for Candidates for the EuPA Young Investigator Prize (PhD)

Call for Candidates for the 2016 EuPA Young Investigator Prize (PhD)

Call for Candidates for the 2016 EuPA Young Investigator Prize (PhD)

RA outcomes and comorbidities and Young Investigator Prize winner

RA outcomes and comorbidities and Young Investigator Prize winner

Heinz Maier-Leibnitz Prize: N. Maulide / Karl Ziegler Guest Professorship: D. Enders / EurJIC Young Investigator Prize: K. Ray

Angewandte Chemie International EditionVolume 52, Issue 40 p. 10417-10417 News Heinz Maier-Leibnitz Prize: N. Maulide / Karl Ziegler Guest Professorship: D. Enders / EurJIC Young Investigator Prize: K. Ray First published: 13 August 2013 https://doi.org/10.1002/anie.201306179Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Volume52, Issue40September 27, 2013Pages 10417-10417 RelatedInformation

Heinz‐Maier‐Leibnitz‐Preis: N. Maulide / Karl‐Ziegler‐Gastprofessur: D. Enders / EurJIC Young Investigator Prize: K. Ray

Angewandte ChemieVolume 125, Issue 40 p. 10609-10609 Nachrichten Heinz-Maier-Leibnitz-Preis: N. Maulide / Karl-Ziegler-Gastprofessur: D. Enders / EurJIC Young Investigator Prize: K. Ray First published: 13 August 2013 https://doi.org/10.1002/ange.201306179Read the full textAboutPDF ToolsRequest permissionAdd to favorites ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Volume125, Issue40September 27, 2013Pages 10609-10609 This is the German version of Angewandte Chemie. Note for articles published since 1962: Do not cite this version alone. Take me to the International Edition version with citable page numbers, DOI, and citation export. We apologize for the inconvenience. RelatedInformation

Call for Candidates for the EuPA Young Investigator Prize (PhD)

Call for Candidates for the EuPA Young Investigator Prize (PhD)

Learning and doing: operational research and access to HIV treatment in Africa

Learning and doing: operational research and access to HIV treatment in Africa

Notes from the Arbeitsgemeinschaft Dermatologische Forschung (ADF), Berlin

This year’s annual meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) took place during March 5–7, 2009 in beautiful Heidelberg ⁄Germany. In keeping with good ADF tradition, the meeting started with a wonderful workshop on ‘Cancer and Aging’ organized by Karsten Mahnke and Mark Berneburg. The workshop featured talks by Hartmut Geiger (Ulm), Anna Wredenberg (Stockholm) and Alexander Burkle (Konstanz). Other highlights of the meeting included the three ‘Quo Vadis’-lectures by Peter Friedl (‘Imaging vs imagination’, Wurzburg ⁄Nijmegen, Holland), Esther von Stebut-Borschitz (Th1, Th2, Th3, mine!, Mainz) and Khusru Asadullah (‘From ADF abstract to medication: how does it work?’, Berlin) as well as the Gunter Goerz lecture (honouring lifetime academic achievements in investigative dermatology) by Thomas A. Luger (‘The skin and the nervous system’, Munster). Finally, we were honoured by the presence of Harald zur Hausen and his keynote lecture on cancer prophylaxis by immunization – opportunities and possibilities. In addition to 12 ADF members receiving poster or travel awards, the ADF rewarded the following scientists with one of her five prestigious awards (honouring outstanding research achievements within the ADF community): Stefan Martin (Freiburg) obtained the Paul Langerhans-Award (honouring distinguished ADF investigators, sponsor: BiogenIdec) for his important work on the immunologic pathomechanisms of inflammatory skin diseases with a focus on chemical induced allergic contact dermatitis. Verena Kupas (Munster) and Sabine Ring (Heidelberg) received the ECARF ⁄ADF-Award in Allergy Research (sponsor: European Centre for Allergy Research Foundation, Berlin) for their work on regulatory T cells and their role in skin inflammation. The working group of Jurgen Eberle (Berlin) was honoured with the ADF Oncology-Award for his contribution to efficient and selective killing of melanoma cells by new oncolytic adenoviral vectors with doxycycline-inducible expression of CD95L ⁄FasL and Christoffer Gebhardt (Heidelberg) received the Egon Macher-Award (which is the ADF young investigator prize, sponsor: 3M) for his work on RAGE signalling and its role in inflammation and tumor development. The ADF also awarded a research fellowship grant, which went to Amanda Buchau (Munchen). The research fellowship grant, which is cofunded by the ADF and the German Society of Dermatology (DDG), allows young scientists at the beginning of their career to train in experimental dermatology. The ADF gratefully acknowledges the efforts of the local organizing team led by Alexander Enk and Karsten Mahnke (Heidelberg), which made this year’s ADF meeting a great success and lots of fun. Finally, we would like to draw your attention to the next ADF meeting on February 18–20, 2010, which will take place in Lubeck! Moreover, the ADF board of directors recognizes with gratitude the support of the ADF corporate sponsors. For more details, please have a look on the ADF-website on http://www.adf-online.de.

Kisspeptin: A Novel Regulator of Reproductive Function

The UK and international neuroendocrine community was deeply shocked and saddened the unbelievably premature death of Michael Harbuz in Bristol in 2006. Mick was a superb friend and colleague, and played a huge part in the development and activities of the British Neuroendocrine Group/British Society for Neuroendocrinology (BSN), serving as both Membership Secretary and Treasurer between 1999 and 2004. Mick was a leader in the field of neuroendocrine-immune interactions, and brought a great deal of charisma, humour and ability to meetings and conferences. He was also a passionate and committed supporter of the progress of young researchers and of their participation in neuroendocrine events. He recognised that today's postgraduate students and postdoctoral research fellows are tomorrow's neuroendocrine researchers, be it in academia, the health services or industry. To recognise Mick's great commitment to and enthusiasm for postgraduate education both in the University of Bristol and in the BSN, we decided to honour and remember him by instituting the 'Michael Harbuz Young Investigator Prize Lecture' to be delivered annually. Dr Waljit Dhillo from Imperial College London was the inaugural recipient of this award, and presented his lecture at the Annual Meeting of the BSN in Nottingham in September 2007, upon which this review is based. Recent evidence demonstrates that the neuropeptide kisspeptin and its receptor, GPR54, have a fundamental role in initiating the onset of puberty and are important in regulating reproductive function. This review discusses the evidence available from animals and humans demonstrating that kisspeptin potently stimulates the release of gonadotrophins by stimulating the release of gonadotrophin-releasing hormone and that a lack of kisspeptin or GPR54 results in reproductive failure.

Abstracts for the British Congenital Cardiac Association Annual Meeting: The Barbican, London, 24–25 November 2005: Winner of the Young Investigator's Prize: B-Type Natiuretic Peptide (BNP) as a marker of paediatric heart failure

Background: Paediatric heart failure can be difficult to assess. Symptoms vary widely in children who have poor ventricular function on echocardiogram. In addition exercise testing is not possible in young children. BNP has been used in adult heart failure and more recently in paediatrics. We investigated BNP in the setting of a paediatric heart failure and transplantation service to assess its usefulness as a clinical marker of heart failure. Method: Clinical and echocardiographic data were correlated to 126 BNP samples. Patients were 3 weeks to 16 years of age. Left ventricular end-diastolic dimension (LVEDd) was related to normal values for body surface area (z-score). Clinical status was defined using Ross and NYHA scores. Thirty four samples were from patients with normal ventricular function. Of the remainder, most were from patients with idiopathic dilated cardiomyopathy (38), anthracycline cardiotoxicity (15), congenital heart disease (25), viral myocarditis (6) and restrictive cardiomyopathy (6). Analysis: BNP was correlated to parametric data (fractional shortening (FS%)) with pearsons correlation coefficient. For non-parametric data (z-score, NYHA and Ross score), spearmans correlation coefficient was used. Results: Rising BNP levels correlate to deteriorating clinical status with significance to the 0.01 level (Ross and NYHA), Figure 1. There was also correlation, significant to the 0.01 level to FS%, Figure 2. Increasing BNP levels correlated to the increasing LVEDd z-score significant to the 0.05 level. Mean BNP: in ventricular dysfunction 634 pg/ml (S.E.M. = 80), in normal function 11.9 pg/ml (S.E.M. = 1.6). Conclusions: This is the largest study of BNP in paediatric heart failure. The stronger correlation of BNP to NYHA and ROSS than to LVEDD and FS% suggests a useful role in assessment of children with heart failure. We believe it is useful in the outpatient setting particularly when care is shared with general paediatricians. It also appears to be a useful addition in the assessment of heart failure and perhaps timing of transplantation in a specialist centre.

Abstracts for the British Congenital Cardiac Association Annual Meeting: The Barbican, London, 24–25 November 2005: Winner of the Young Investigator's Prize: Omega-3 fatty acids – pharmacological preconditioning for paediatric cardiac surgical patients

Background: Inappropriate systemic inflammatory endothelial and leucocyte activation is a major pathogenic component of post-operative low cardiac output syndrome (LCOS) and associated pulmonary oedema, low urine output, and generalised oedema, in paediatric cardiac surgery. We hypothesised that acute pre-treatment with a parenteral nutrition component omega-3 fatty acid infusion in-vitro, would prevent the pattern of leucocyte and endothelial activation seen in paediatric cardiac surgery through induction of preconditioning. Methods: Endothelial cells were isolated from saphenous vein of 75 adult cardiac surgery patients, grown in monolayers, pre-treated, and then stimulated with either endotoxin (LPS), TNFalpha, or complement C5a (prime mediators of systemic inflammation with paediatric cardiac surgery). Endothelial production of the neutrophil recruiting cytokines IL-6, IL-8, and endothelial expression of the neutrophil adherence receptors E-Selectin, ICAM-1 were assessed. The effects on the inflammatory pro-coagulant response of the endothelium i.e. loss of surface thrombomodulin and production of tissue factor were also examined. Similar methods were employed using isolated peripheral blood neutrophils. The effects on endothelial nuclear translocation of the acute inflammatory transcription factor NFkB and the heat shock protein (HSP72) response were investigated for mechanistic insight. Results: Four hours pre-treatment with the omega-3 infusion prevented endothelial release of neutrophil recruiting cytokines IL-6 and IL-8, also prevented upregulation of endothelial receptors required for neutrophil adherence E-Selectin and ICAM-1, and maintained surface anticoagulant thrombomodulin levels, in response to stimulation with LPS (Table 1) or TNFalpha.

Journal of Ecology news

<i>Journal of Ecology</i> news

Notes from the Arbeitsgemeinschaft Dermatologische Forschung (ADF), Berlin,

The 2005 ADF Annual Meeting was held in Innsbruck, Austria, 3–5 March, 2005, featuring an acclaimed workshop on ‘Wound healing and angiogenesis.’ Speakers: K. Alitalo, M. Detmar, S. Werner, N. Fusenig and others, as well as J. Ring (Munich), M. Maurer (Berlin), J. Baron (Aachen), and R. Dummer (Zürich) as ‘Quo vadis’ speakers, and D. Bickers (New York) as Günter-Goerz-Lecturer (honoring lifetime academic achievements in investigative dermatology) and G. Wick (Innsbruck) as Special Guest Lecturer. Besides six poster and six travel awards, several prestigious awards were bestowed at the Innsbruck ADF Meeting to honor outstanding research achievements within the ADF community. Awardees: ECARF-ADF Award in Allergy Research (sponsor: European Center for Allergy and Research Foundation, Berlin): Professor E. Jensen-Jarolim, University of Vienna, Institute of Physiology and Pathphysiology, for her work suggesting that antiacid medication promotes type I allergies and Dr J. Gutermuth, Center for Allergy and Environment, Department of Dermatology, Technical University of Munich, for his work on intranasal DC vaccination against airborne allergens. Egon-Macher Award (Young Investigator Prize, sponsor: 3M): Dr D. Schrama, Department of Dermatology, University of Würzburg, for demonstrating a shift from systemic to site-specific memory by tumor-targeted IL-2 in the mouse model of B16-melanoma. Langerhans-Award for distinguished investigators within the ADF community (sponsor: BiogenIdec): Dr H. Jonuleit, Department of Dermatology, University of Mainz, for his work on the development and function of regulatory T cells and Professor S. Beissert, Department of Dermatology, University of Münster, for his contributions to analyzing the immunological mechanisms that underlie T cell-mediated skin inflammation. ADF Oncology Award (sponsor: Erwin and Irmgard Egner-Foundation): Professor A. Schneeberger, University of Vienna, for his contributions to the development of innovative vaccination strategies in melanoma therapy. The 2006 ADF Annual Meeting is held in Aachen, Germany, March 23–25, 2006. Besides the prizes listed above, as well as lavish poster and travel awards, two additional awards for outstanding translational research that exemplarily bridges the bench-to-bedside gap will be awarded on-site (sponsor: Dermatologikum, Hamburg). Details on the 2006 Annual Meeting and the ADF Awards, see http://www.adf-online.de The ADF Board of Directors wishes to honor, and to call attention to, selected outstanding papers of general interest that were recently published by ADF members (bold print) in high-ranking non-dermatological journals. Such highlights include, for example: Rupec R A, Jundt F, Rebholz B, Eckelt B, Weindl G, Herzinger T, Flaig M J, Moosmann S, Plewig G, Dorken B, Forster I, Huss R, Pfeffer K. Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. Immunity 2005: 22: 479–491. Traidl-Hoffmann C, Mariani V, Hochrein H, Karg K, Wagner H, Ring J, Mueller M J, Jakob T, Behrendt H. Pollen-associated phytoprostanes inhibit dendritic interleukin-12 production and augment T helper type 2 polarization. J Exp Med 2005: 201: 627–635. Sitaru C, Mihai S, Otto C, Chiriac M T, Hausser I, Dotterweich B, Saito H, Rose C, Ishiko A, Zillikens D. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005: 115: 870–878. Petzelbauer P, Zacharowski P A, Miyazaki Y, Friedl P, Wickenhauser G, Castellino F J, Gröger M, Wolff K, Zacharowski K. The fibrin-derived peptide Bβ15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 2005: 11: 298–304. Meller S, Winterberg F, Gilliet M, Mueller A, Lauceviciute I, Rieker J, Neumann N J, Kubitza R, Gombert M, Bunemann E, Wiesner U, Franken-Kunkel P, Kanzler H, Dieu-Nosjean R, Amara A, Ruzicka T, Lehmann P, Zlotnik A, Homey B. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005: 52: 1504–1516. Kriehuber E, Bauer W, Charbonnier A S, Winter D, Amatschek S, Tamandl D, Schweifer N, Stingl G, Maurer D. Balance between NF-kappaB and JNK/AP-1 activity controls dendritic cell life and death. Blood 2005: 106: 75–83. Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005: 24: 2885–2895. Maurer M, Wedemeyer J, Metz M, Piliponsky A M, Weller K, Chatterjea D, Clouthier D E, Yanagisawa M M, Tsai M, Galli S J. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 2005: 432: 512–516. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, Wagner E F. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005: 437: 369–375. Schön M P, Boehncke W H. Psoriasis. N Engl J Med 2005: 352: 1899–1912. Reich K, Nestle F O, Papp K, Ortonne J P, Evans R, Guzzo C, Li S, Dooley L T, Griffiths C E; EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005: 366: 1367–1374.

Journal of Ecology news

<i>Journal of Ecology</i> news